MICROPLATE READERS


BMG Labtech’s Vantastar solution


generation of a luminescent signal via the intermediate luciferin. Te amount of cellular ROS naturally increases upon treatment with a ROS inducer like Menadione (Fig.2a). Antioxidants like N-Acetyl-L-cysteine (NAC), on the other hand, have the potential to inhibit cellular ROS production. HeLa cells were treated with a high dose (50 µM) of Menadione and on top with increasing concentrations of NAC (12.5 to 400 µM). Te measurement of luminescence in the Vantastar revealed a dose-dependent reduction of cellularly produced H2


increasing NAC concentrations (Fig.2b). BMG Labtech’s Vantastar plate reader is an ideal tool to measure luminescence- based assays with maximum ease of use. Te Enhanced Dynamic Range (EDR) function ensures each well is read with the optimal gain and highest sensitivity. Tis allowed to miniaturise the assay from a 96-well to a 384-well format. Furthermore, the Vantastar automatically applies the


O2


with


Fig. 2. (a) Cellular generation of ROS and impact of ROS-inducing Menandione and the antioxidant N-Acetylcysteine. (b) Luminescent signal obtained from HeLa cells treated with Menandione and increasing concentrations of N-Acetyl-L-cysteine using the ROS-Glo assay


ideal focal height and blocks unwanted stray signal from adjacent wells during the detection.


Te plate reader enables user-friendly luminescence measurements with significantly reduced error susceptibility. Tese features combined with the homogenous assay format of the metabolic assay kits (Glucose-Glo, Lactate-Glo and


ROS-Glo) represent the ideal combination to analyse cellular metabolism also in a miniaturised format.


Ann-Cathrin Volz is with BMG Labtech www.bmglabtech.com


www.scientistlive.com 23


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60